June 13, 2017
Invokana bests placebo for several risks with type 2 diabetes patients
Results from the CANVAS Program showed Invokana (canagliflozin) compared to placebo actually can reduce combined risk of cardiovascular (CV) death, myocardial infarction (MI), and nonfatal stroke, in patients with type 2 diabetes mellitus (T2DM) at risk for or with a history of CV disease.